JPRN-jRCT2080222818未知3 期
A phase III parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPA
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •Patients diagnosed with Parkinson's disease in stages 2 to 4 on the modified Hoehn & Yahr scale(on time).
排除标准
- •- Patients with a history of hypersensitivity to ropinirole.
- •- Patients with clinically significant renal impairment or hepatic dysfunction.
- •- Patients who have any cutaneous abnormality at the planned application site that could be aggravated by application of the investigational product.
研究者
相似试验
未知
3 期
Phase III study of HOB-294 in patients with overactive bladder.Overactive bladderJPRN-jRCT2080221272Hisamitsu Pharmaceutical Co., Inc.
进行中（未招募）
1 期
A Phase IIIb study to openly compare a group treated with only pegylated interferon alfa-2a (PEG-IFN) to an untreated group in children with chronic hepatitis B (CHB) who are HBeAg positive (a marker of their stage of CHB infection).EUCTR2011-002732-70-DEF. Hoffmann-La Roche Ltd161
进行中（未招募）
1 期
A Phase IIIb study to openly compare a group treated with only pegylated interferon alfa-2a (PEG-IFN) to an untreated group in children with chronic hepatitis B (CHB) who are HBeAg positive (a marker of their stage of CHB infection).Treatment of HBeAg positive chronic hepatitis B (CHB) in children.MedDRA version: 20.0Level: LLTClassification code 10052552Term: Hepatitis B virusSystem Organ Class: 100000004848EUCTR2011-002732-70-PLF. Hoffmann-La Roche Ltd161
进行中（未招募）
1 期
A Phase IIIb study to openly compare a group treated with only pegylated interferon alfa-2a (PEG-IFN) to an untreated group in children with chronic hepatitis B (CHB) who are HBeAg positive (a marker of their stage of CHB infection).Treatment of HBeAg positive chronic hepatitis B (CHB) in children.MedDRA version: 14.1Level: LLTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-002732-70-ITF. HOFFMANN - LA ROCHE LTD.161
进行中（未招募）
1 期
A Phase IIIb study to openly compare a group treated with only pegylated interferon alfa-2a (PEG-IFN) to an untreated group in children with chronic hepatitis B (CHB) who are HBeAg positive (a marker of their stage of CHB infection).EUCTR2011-002732-70-BGF. Hoffmann-La Roche Ltd161